Compare SCHW & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCHW | AZN |
|---|---|---|
| Founded | 1971 | 1992 |
| Country | United States | United Kingdom |
| Employees | 32700 | 96100 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1B | 316.4B |
| IPO Year | N/A | N/A |
| Metric | SCHW | AZN |
|---|---|---|
| Price | $98.40 | $203.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 1 |
| Target Price | ★ $112.56 | N/A |
| AVG Volume (30 Days) | ★ 7.9M | 1.8M |
| Earning Date | 04-16-2026 | 04-29-2026 |
| Dividend Yield | 1.30% | ★ 1.57% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.97 | $10.35 |
| Revenue Next Year | $8.93 | $6.43 |
| P/E Ratio | ★ $20.51 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $73.76 | $66.16 |
| 52 Week High | $107.50 | $212.71 |
| Indicator | SCHW | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 64.61 | 61.97 |
| Support Level | $99.51 | $182.39 |
| Resistance Level | $106.02 | $211.32 |
| Average True Range (ATR) | 2.45 | 3.36 |
| MACD | 0.77 | 0.22 |
| Stochastic Oscillator | 99.27 | 83.60 |
Charles Schwab is one of the largest retail-oriented financial-services companies in the US, with $11.9 trillion in client assets across its brokerage, banking, asset management, custody, financial advisory, and wealth-management businesses at the end of 2025. While best known for its retail brokerage offering, Schwab generates the lion's share of its revenue and profits through its Charles Schwab Bank and asset management segments. The firm is a dominant player in registered investment advisor custody, with over 40% market share, and has recently pushed into wealth management with robo-advisory, direct indexing, and other managed-investment solutions.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.